IL2 and neoplasm: Taken together, this data suggest that disruption of lymphatic Nr2f6 converts tumor-infiltrating T cells into IFNγ- and IL-2-hypersecreting effector cells, apparently sufficient to prime the TIME for immune checkpoint therapy to more effectively control tumor growth.